

# Justine A Barletta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5825828/publications.pdf>

Version: 2024-02-01

80  
papers

5,452  
citations

136950

32  
h-index

82547

72  
g-index

81  
all docs

81  
docs citations

81  
times ranked

5725  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 1023.	7.1	1,192
2	Somatic <i>ERCC2</i> Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. <i>Cancer Discovery</i> , 2014, 4, 1140-1153.	9.4	506
3	Overview of the 2022 WHO Classification of Thyroid Neoplasms. <i>Endocrine Pathology</i> , 2022, 33, 27-63.	9.0	388
4	Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1426-1433.	27.0	290
5	The Impact of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma on Rates of Malignancy for Fine-Needle Aspiration Diagnostic Categories. <i>Thyroid</i> , 2015, 25, 987-992.	4.5	228
6	Risk Stratification of Follicular Variant of Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2013, 23, 273-279.	4.5	164
7	Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. <i>Cancer</i> , 2017, 123, 4346-4355.	4.1	138
8	Prognostic significance of grading in lung adenocarcinoma. <i>Cancer</i> , 2010, 116, 659-669.	4.1	123
9	Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. <i>Hypertension</i> , 2019, 73, 885-892.	2.7	121
10	BRAF V600E mutation-specific antibody: A review. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 400-408.	1.5	116
11	Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. <i>Modern Pathology</i> , 2015, 28, 1504-1514.	5.5	111
12	Fine-Needle Aspiration Diagnoses of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma. <i>American Journal of Clinical Pathology</i> , 2015, 144, 850-857.	0.7	108
13	Preoperative Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Prospective Analysis. <i>Thyroid</i> , 2016, 26, 1466-1471.	4.5	108
14	Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists. <i>Modern Pathology</i> , 2018, 31, 39-55.	5.5	107
15	Molecular Alterations in Partially-Encapsulated or Well-Circumscribed Follicular Variant of Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2013, 23, 1256-1262.	4.5	104
16	Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. <i>Clinical Cancer Research</i> , 2018, 24, 1546-1553.	7.0	86
17	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of <i>Carcinomas</i> Harboring <i>RAS</i> Mutations. <i>Thyroid</i> , 2017, 27, 506-511.	4.5	84
18	Succinate Dehydrogenase-deficient Tumors. <i>Advances in Anatomic Pathology</i> , 2012, 19, 193-203.	4.3	66

#	ARTICLE	IF	CITATIONS
19	Radiation-associated neoplasia: clinical, pathological and genomic correlates. <i>Histopathology</i> , 2017, 70, 70-80.	2.9	65
20	Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier. <i>Thyroid</i> , 2016, 26, 911-915.	4.5	62
21	Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and Adults. <i>Thyroid</i> , 2019, 29, 1097-1104.	4.5	57
22	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. <i>Endocrine</i> , 2018, 59, 143-150.	2.3	57
23	International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 96-104.	1.6	57
24	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2020, 80, 4476-4486.	0.9	49
25	Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. <i>Thyroid</i> , 2021, 31, 933-940.	4.5	45
26	Absence of BRAF V600E in non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma. <i>Histopathology</i> , 2015, 67, 579-582.	2.9	44
27	Immunohistochemical Staining of Thyroidectomy Specimens for PTEN Can Aid in the Identification of Patients With Cowden Syndrome. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1505-1511.	3.7	42
28	HER2 as a target in invasive urothelial carcinoma. <i>Cancer Medicine</i> , 2015, 4, 844-852.	2.8	41
29	EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1259-1261.	27.0	41
30	A user's guide to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). <i>Histopathology</i> , 2018, 72, 53-69.	2.9	40
31	GATA3 expression in gestational trophoblastic tissues and tumours. <i>Histopathology</i> , 2015, 67, 636-644.	2.9	39
32	Differential Growth Rates of Benign vs. Malignant Thyroid Nodules. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4642-4647.	3.6	38
33	A phase II study of nivolumab (N) plus ipilimumab (I) in radiiodine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6513-6513.	1.6	34
34	Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations. <i>Endocrine Pathology</i> , 2021, 32, 35-43.	9.0	33
35	Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis. <i>Endocrine Pathology</i> , 2019, 30, 43-48.	9.0	32
36	Features and Outcome of Autonomous Thyroid Nodules in Children: 31 Consecutive Patients Seen at a Single Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3856-3862.	3.6	29

#	ARTICLE	IF	CITATIONS
37	Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E-Driven Papillary Thyroid Cancer Patients. <i>Clinical Cancer Research</i> , 2021, 27, 4256-4264.	7.0	29
38	Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 1255-1261.	4.5	28
39	Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules. <i>Cancer Cytopathology</i> , 2018, 126, 86-93.	2.4	27
40	Everolimus in Anaplastic Thyroid Cancer: A Case Series. <i>Frontiers in Oncology</i> , 2019, 9, 106.	2.8	25
41	The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas. <i>Endocrine Pathology</i> , 2017, 28, 171-176.	9.0	24
42	Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2367-2373.	7.0	24
43	Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. <i>Thyroid</i> , 2019, 29, 666-673.	4.5	24
44	How Are Childhood Thyroid Nodules Discovered: Opportunities for Improving Early Detection. <i>Journal of Pediatrics</i> , 2014, 164, 658-660.	1.8	23
45	Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. <i>European Journal of Endocrinology</i> , 2017, 177, 439-444.	3.7	23
46	Anaplastic thyroid carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2020, 37, 248-256.	1.5	23
47	Genetic and Histopathologic Intertumor Heterogeneity in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1792-1796.	3.6	22
48	Successful Management of a Patient with Malignant Thyroid Teratoma. <i>Thyroid</i> , 2017, 27, 125-128.	4.5	21
49	Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP). <i>Endocrine Pathology</i> , 2018, 29, 68-74.	9.0	21
50	Ketogenic diet combined with antioxidant N-acetylcysteine inhibits tumor growth in a mouse model of anaplastic thyroid cancer. <i>Surgery</i> , 2020, 167, 87-93.	1.9	20
51	Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021, 110, 62-72.	2.0	20
52	A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6023-6023.	1.6	19
53	Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma. <i>Endocrine Pathology</i> , 2018, 29, 357-364.	9.0	18
54	A case of primary secretory carcinoma of the thyroid with high-grade features. <i>Histopathology</i> , 2017, 71, 665-669.	2.9	15

#	ARTICLE	IF	CITATIONS
55	Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas. <i>Histopathology</i> , 2021, 79, 427-436.	2.9	15
56	A potential diagnostic pitfall for hobnail variant of papillary thyroid carcinoma. <i>Histopathology</i> , 2020, 76, 707-713.	2.9	14
57	Histological features of <i>BRAF</i> V600E mutant anaplastic thyroid carcinoma. <i>Histopathology</i> , 2020, 77, 314-320.	2.9	14
58	Adrenal Tumors in Adults. <i>Surgical Pathology Clinics</i> , 2015, 8, 725-749.	1.7	13
59	Applications of Immunohistochemistry to Endocrine Pathology. <i>Advances in Anatomic Pathology</i> , 2018, 25, 413-429.	4.3	13
60	Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study. <i>Endocrine Pathology</i> , 2022, 33, 371-377.	9.0	13
61	Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer. <i>Journal of the American College of Surgeons</i> , 2017, 224, 1021-1027.	0.5	12
62	Completion Thyroidectomy is Less Common Following Updated 2015 American Thyroid Association Guidelines. <i>Annals of Surgical Oncology</i> , 2021, 28, 484-491.	1.5	12
63	Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component. <i>Endocrine Pathology</i> , 2020, 31, 283-290.	9.0	11
64	Predictors of Bilateral Disease in Pediatric Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4242-e4250.	3.6	10
65	Genomic profile of columnar cell variant of papillary thyroid carcinoma. <i>Histopathology</i> , 2021, 79, 491-498.	2.9	10
66	Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer. <i>Surgery</i> , 2022, 171, 227-234.	1.9	10
67	Role of Sonographic Characteristics of Thyroid Bed Lesions Identified Following Thyroidectomy in the Diagnosis or Exclusion of Recurrent Cancer. <i>Radiology</i> , 2021, 299, 374-380.	7.3	8
68	Poorly Differentiated Thyroid Carcinoma. <i>Surgical Pathology Clinics</i> , 2014, 7, 475-489.	1.7	7
69	Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas. <i>Thyroid</i> , 2019, 29, 1279-1285.	4.5	7
70	Thyroid Tumors You Don't Want to Miss. <i>Surgical Pathology Clinics</i> , 2019, 12, 901-919.	1.7	7
71	Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. <i>Scientific Reports</i> , 2020, 10, 20135.	3.3	4
72	Everolimus in anaplastic thyroid cancer: A case series.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18112-e18112.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2019, 37, 479-479.	1.6	3
74	Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma. American Journal of Case Reports, 2020, 21, e927415.	0.8	3
75	Recipient of the 2021 Endocrine Pathology Society Lifetime Achievement Award: Dr. Ronald A. DeLellis. Endocrine Pathology, 2021, 32, 429-431.	9.0	2
76	Endocrine Pathology: Advances, Updates, and Diagnostic Pearls. Surgical Pathology Clinics, 2019, 12, xi-xii.	1.7	1
77	Squamous cell carcinoma of the oral cavity (SCCOC) in young patients: The Dana Farber Cancer Institute experience.. Journal of Clinical Oncology, 2013, 31, 6054-6054.	1.6	0
78	Genomic landscape of high-grade T1 micropapillary bladder tumors.. Journal of Clinical Oncology, 2015, 33, 299-299.	1.6	0
79	Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC).. Journal of Clinical Oncology, 2015, 33, e15519-e15519.	1.6	0
80	Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma. American Journal of Case Reports, 2020, 21, e927415.	0.8	0